A Retrospective Observational Study of Safety and Effectiveness of Abemaciclib in Chinese Patients with Breast Cancer

20260 citationsJournal Articlehybrid Open Access

Authors

Fangyuan Zhao · Peking University

Yaxin Liu · Ministry of Education

Hanfang Jiang · Ministry of Education

Liu Yang · Lilly (China)

Qinyi Zhu · Lilly (China)

X. Ma · Lilly (China)

Huiping Li · Ministry of Education

Abstract

In this largest real-world study of abemaciclib in China to date, abemaciclib was well tolerated with no new safety signals, and its effectiveness was consistent with prior trials, confirming its positive benefit-risk profile in real-world settings.

Topics & Keywords

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Advances in Therapy

DOI: 10.1007/s12325-026-03538-y

Field-Weighted Citation Impact: 0.00